Ulike prevensjonsmetoder

Dette dokumentet er basert på det profesjonelle dokumentet Valg av prevensjonsmiddel. Referanselisten for dette dokumentet vises nedenfor.

1. Ræder MB, Johansen M, Offerdal K. Prevensjon. Veileder i gynekologi. Norsk gynekologisk forening. Oslo: 2021. Siden besøkt 07.10.22 www.legeforeningen.no 
2. Reseptregisteret. Folkehelseinstituttet. Søk 04.10.22 www.reseptregisteret.no 
3. Juvkam KH, Gudim HB. Medikamentell behandling av menstruasjonsrelaterte plager. Tidsskr Nor Legeforen 2011; 9: 956-8. doi:10.4045/tidsskr.10.0300 DOI 
4. Curtis KM, Peipert JF. Long-Acting Reversible Contraception. N Engl J Med 2017; 376: 461-68. pmid:28146650 PubMed 
5. Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception. 2017 Jan;95(1):17-39. Epub 2016 Oct 19. PMID: 27771475 PubMed 
6. Statens legemiddelverk. Råd til helsepersonell. Anbefalte hormonelle prevensjonsmidler. Sist oppdatert 27.09.22. Siden besøkt 07.10.22. legemiddelverket.no 
7. Lopez LM, Grey TW, Stuebe AM, Chen M, Truitt ST, Gallo MF. Combined hormonal versus nonhormonal versus progestin‐only contraception in lactation. Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No.: CD003988. DOI: 10.1002/14651858.CD003988.pub2. Accessed 17 February 2021. The Cochrane Library 
8. P-implantat med etonogestrel - blødningsforstyrrelser og effekt hos overvektige kvinner. Relis.no. 03.06.15
9. Bratberg Å, Havnen GC. Gestagener og risiko for fostermisdannelser. Relis.no. Publisert 20.04.16. relis.no 
10. Westhoff CL, Keder LM, Gangestad A, et al. Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system. Contraception 2019. pmid:31786203 PubMed 
11. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010; 15: 4-16. doi:10.3109/13625180903427675 DOI 
12. Widnes SF, Myklebust ÅJ. Forlenget bruk av hormonspiral hos premenopausale kvinner. Utposten 2016; 45(2): 46-7 relis.no 
13. Turok DK, Gero A, Simmons RG et al. Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception. N Engl J Med. 2021 Jan 28;384(4):335-344. PMID: 33503342 PubMed 
14. Henkel A, Lerma K, Reyes G et al. Lactogenesis and breastfeeding after immediate vs delayed birth-hospitalization insertion of etonogestrel contraceptive implant: a noninferiority trial. Am J Obstet Gynecol. 2022 Aug 12:S0002-9378(22)00644-5. Epub ahead of print. PMID: 35964661 PubMed 
15. L3.11.2 Gestagen (antikonsepsjon). Norsk legemiddelhåndbok. Publisert 03.09.16. Siden besøkt 07.10.22 www.legemiddelhandboka.no 
16. Sjekkliste og informasjon til forskrivere. Statens Legemiddelverk 2018 legemiddelverket.no 
17. Schink T, Princk C, Braitmaier M, Haug U. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data. BJOG. 2022 Jul 25. Epub ahead of print. PMID: 35876787.
18. Oedingen C, Scholz S, Razum O. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose. Thromb Res. 2018; 165:68-78. PMID: 29573722 PubMed 
19. Roach RE, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database of Syst Rev 2015, Issue 8. Art. No.: CD011054. DOI: 10.1002/14651858.CD011054.pub2. DOI 
20. Reiter L, Havnen GC. Forlenget p-pillesyklus – fordeler og ulemper. Relis.no. Publisert 01.10.15
21. Nilsen T, Nordmo E. Bytte til p-piller med lavere risiko for blodpropp – bør det standardiseres? Norsk Farmaceutisk Tidsskrift 26.10.15
22. Cleland K, Zhu H, Goldstuck N et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012 Jul;27(7):1994-2000. Epub 2012 May 8. PMID: 22570193 PubMed 
23. Trussel J. Contraceptive failure in the United States. Contraception 2011; 83: 397-404. doi:10.1016/j.contraception.2011.01.021 DOI 
24. Berglund Scherwitzl E, Gemzell Danielsson K, Sellberg JA et al. Fertility awareness-based mobile application for contraception. Eur J Contracept Reprod Health Care. 2016 Jun;21(3):234-41. Epub 2016 Mar 22. PMID: 27003381 PubMed 
25. Shen J, Che Y, Showell E et al. Interventions for emergency contraception. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD001324. DOI: 10.1002/14651858.CD001324.pub6. The Cochrane Library 
26. Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA. 2021 Dec 28;326(24):2507-2518. PMID: 34962522 PubMed 
27. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD004425. DOI: 10.1002/14651858.CD004425.pub6 DOI 
28. ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. Obstet Gynecol. 2019 Feb;133(2):e128-e150. doi: 10.1097/AOG.0000000000003072. Erratum in: Obstet Gynecol. 2019 Jun;133(6):1288. PMID: 30681544 PubMed 
29. Statens legemiddelverk. Preparatomtale (SPC) Diane. www.legemiddelverket.no/legemiddelsok. Sist endret: 17.06.2020. Siden besøkt 12.02.2021
30. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135. doi:10.1136/bmj.h2135 DOI 
31. Bratberg Å, Wesnes A. Valg av prevensjon til kvinner med polycystisk ovariesyndrom (PCOS). RELIS. Publisert 02.02.2017. relis.no 
32. Vanky E, Underdal MO, Stauri RVK, Kjøtrød S. Polycystisk ovariesyndrom. Veileder i gynekologi. Norsk gynekologisk forening. Oslo: 2021. Siden besøkt 10.10.22 www.legeforeningen.no 
33. Tellum T, Ringen IM, Veddeng A et al. Endometriose og adenomyose. Veileder i gynekologi. Norsk gynekologisk forening. Oslo: 2021. Siden besøkt 10.10.22 www.legeforeningen.no 
34. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database of Systematic Reviews 2012; 3: CD002122. DOI: 10.1002/14651858.CD002122.pub2 DOI 
35. Reiter L, Nakken KO. Prevensjon for kvinner som bruker antiepileptika. Tidsskr Nor Legeforen 2016; 136: 32-4. doi:10.4045/tidsskr.14.1559 DOI 
36. Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception 2017; 95: 571-7. pmid:28288788 PubMed 
37. Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016 Aug 18;(8):CD008452. doi: 10.1002/14651858.CD008452.pub4. The Cochrane Library 
38. Shawe J, Ceulemans D, Akhter Z et al. Pregnancy after bariatric surgery: Consensus recommendations for periconception, antenatal and postnatal care. Obes Rev. 2019 Nov;20(11):1507-1522. Epub 2019 Aug 16. PMID: 31419378 PubMed 
39. Lethaby A, Wise MR, Weterings MAJ, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2019, Issue 2. Art. No.: CD000154. DOI: 10.1002/14651858.CD000154.pub3. Accessed 17 February 2021. The Cochrane Library 
40. Sacco S, Merki-Feld GS, Ægidius KL et al. European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017 Oct 30;18(1):108. Erratum in: J Headache Pain. 2018 Sep 10;19(1):81. PMID: 29086160 PubMed 
41. Pagano HP, Zapata LB, Berry-Bibee EN, et al.. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception 2016 Dec; 94(6): 641-649. pmid:27364100 PubMed 
42. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry 2016 Nov; 73(11): 1154-1162. pmid:27680324 PubMed 
43. Skovlund CW, Mørch LS, Kessing LV, et al. Association of Hormonal Contraception With Suicide Attempts and Suicides. Am J Psychiatry 2017 Nov 17; Epub ahead of print: appiajp201717060616. pmid: 29145752 PubMed 
44. Nasjonal kompetansetjeneste for svangerskap og revmatiske sykdommer (NKSR). Nasjonal veileder for svangerskap og revmatiske sykdommer. Trondheim; sist oppdatert okt 2022, siden besøkt 10.10.22 www.nksr.no 
45. Valen M, Norby G, Lerang K et al. SLE. Bindevevssykdommer og inflammatoriske myopatier. Norsk revmatologisk forening. Nasjonal veileder i revmatologi. Publisert 26.11.2020. Siden besøkt 19.02.2021 norskrevmatologi.no 
46. Weill A. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: Cohort study. BMJ 2016. doi:10.1136/bmj.i2002 DOI 
47. Antikonception - behandlingsrekommendation. Läkemedelsverket 2014
48. Mørch LS, Skovlund CW, Hannaford PC et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2017 Dec 7;377(23):2228-2239. PMID: 29211679.
49. Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol 2018. pmid:29346467 PubMed 
50. Brabaharan S, Veettil SK, Kaiser JE et al. Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies. JAMA Netw Open. 2022 Jan 4;5(1):e2143730. PMID: 35029663 PubMed 
51. Levin G, Dior UP, Gilad R et al. Pelvic inflammatory disease among users and non-users of an intrauterine device. J Obstet Gynaecol. 2021 Jan;41(1):118-123. Epub 2020 Mar 9. PMID: 32148134 PubMed 
52. Reed SD, Zhou X, Ichikawa L et al.; APEX-IUD study team. Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study. Lancet. 2022 Jun 4;399(10341):2103-2112. Erratum in: Lancet. 2022 Sep 3;400(10354):732. PMID: 35658995.
53. Armstrong MA, Raine-Bennett T, Reed SD et al. Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion. JAMA Netw Open. 2022 Feb 1;5(2):e2148474. PMID: 35226086 PubMed 
54. Ohannessian A, Levy A, Jaillant N et al. A French survey of contraceptive implant migration to the pulmonary artery. Contraception. 2019 Oct;100(4):255-257. doi: 10.1016/j.contraception.2019.05.016. Epub 2019 Jun 10. PMID: 31194964. PubMed 
55. Kang S, Niak A, Gada N et al. Etonogestrel implant migration to the vasculature, chest wall, and distant body sites: cases from a pharmacovigilance database. Contraception. 2017 Dec;96(6):439-445. Epub 2017 Sep 1. PMID: 28867440. PubMed 
56. Zhang S, Batur P, Martin C 3rd, Rochon PJ. Contraceptive Implant Migration and Removal by Interventional Radiology. Semin Intervent Radiol. 2018 Mar;35(1):23-28. Epub 2018 Apr 5. PMID: 29628612 PubMed 
57. Thorkildsen RD, Thu F, Myrseth LE, Røkkum M. Major nerve injury in association with use of contraceptive implants. Tidsskr Nor Laegeforen. 2021 Apr 15;141(7). English, Norwegian. PMID: 33950659. PubMed